A new Cell Reports Medicine study (Dec 2025) found that restoring the brain’s NAD+ balance reversed Alzheimer’s-like pathology and restored cognition in mice. Here’s what it means and what it doesn’t yet.
Alzheimer’s: a century-old assumption is being challenged
For more than 100 years, Alzheimer’s disease (AD) has largely been treated as a one-way road: prevent it if possible, slow it if not—because the prevailing belief was that meaningful recovery wasn’t realistic once the disease was established.
A research team from Case Western Reserve University, University Hospitals, and the Louis Stokes Cleveland VA Medical Center has now published findings that challenge that assumption—at least in preclinical models. Their work asks a bold question: if the brain is already severely affected, can it recover function when a key biological imbalance is corrected?
The study in one paragraph
Published online December 22, 2025 in Cell Reports Medicine, the study (Chaubey et al.) examined human Alzheimer’s brain tissue and tested two established Alzheimer’s mouse models—one primarily driven by amyloid pathology (5xFAD) and one driven by tau pathology (PS19). The researchers found a major disruption in NAD+ homeostasis (the brain’s ability to maintain healthy NAD+ levels) in both human Alzheimer’s brains and the mouse models, then used a pharmacologic compound (P7C3-A20) designed to restore NAD+ balance.
In mice, this approach not only helped prevent disease onset when used early—but, notably, also reversed multiple disease features and restored cognitive function even when treatment started at advanced stages.
Why NAD+ matters (and why it’s getting attention in longevity medicine)
NAD+ (nicotinamide adenine dinucleotide) is a central molecule involved in cellular energy production and resilience. NAD+ levels naturally decline with age across the body, including in the brain—making it a frequent topic in brain health and longevity research.
In this study, the researchers reported that NAD+ disruption was more severe in Alzheimer’s disease than in typical aging, and that the degree of pathology correlated with loss of NAD+ homeostasis.
The implication: if the brain’s “energy economy” collapses, critical functions suffer – potentially contributing to neurodegeneration and cognitive decline.
What “reversal” looked like in the mice
The authors didn’t focus on a single outcome. They reported improvements across several hallmark domains that typically deteriorate in Alzheimer’s-like disease models, including:
- Reduced tau phosphorylation and other pathological signals
Improvements in blood–brain barrier integrity and neuroinflammation - Reduced oxidative stress and DNA damage
- Better hippocampal neurogenesis and synaptic plasticity
- Full recovery in cognitive testing (in the studied models)
They also reported normalization of plasma phosphorylated tau 217 (p-tau217) in mice a blood biomarker now used clinically in the Alzheimer’s diagnostic landscape highlighting a potential measurable marker for future trials aimed at recovery rather than only slowing decline.
At Qualevita, NAD+ is often part of a personalized treatment program focused on recovery, performance, or long-term vitality.
What this means for people and families today
This study is best understood as a proof-of-principle:
- The findings are preclinical (animal models + analysis of human tissue), not a demonstration of reversal in people.
- Alzheimer’s disease remains a uniquely human condition, and many promising mouse-model results do not translate into effective human treatments.
- The authors themselves emphasize the need for carefully designed human clinical trials to determine whether the effect can translate to patients.
Still, the broader signal is meaningful: the work supports a “recovery mindset” as biologically plausible, at least under certain conditions, rather than treating neurodegeneration as inevitably permanent once established.
How Qualevita views developments like this
At Qualevita, we track research at the intersection of metabolic health, brain aging, inflammation, and resilience, because these domains shape long-term cognitive outcomes. Breakthrough preclinical studies like this one are valuable because they:
- identify new therapeutic targets (e.g., energy balance and NAD+ homeostasis),
- suggest new trial endpoints (such as biomarker-supported recovery),
- and refine what “brain health” strategies might eventually look like in clinical care.
At the same time, we separate scientific promise from clinical proof. Today, Alzheimer’s prevention and risk reduction still rely on evidence-based fundamentals as cardiometabolic health, sleep, exercise, vascular risk control, and early clinical evaluation when symptoms appear.
It is not a proven human therapy yet but it strengthens the case that the brain may retain more capacity for repair than previously assumed, and that future Alzheimer’s trials may aim for more than slowing decline. Study
Book your NAD+ IV at Qualevita and experience the difference.
Any other questions? Message us directly on WhatsApp.